Financial Performance - The company reported revenue of approximately HKD 519.7 million for the fiscal year 2024, a decrease from HKD 961.3 million in 2023, primarily due to a decline in sales volume [6]. - The gross profit for the year was HKD 29.7 million, compared to a gross loss of HKD 35.6 million in the previous year, resulting in a gross margin of 5.7% [9]. - The company achieved a profit attributable to owners of approximately HKD 1.3 million, a significant turnaround from a loss of HKD 52.7 million in the prior year [12]. - Total assets decreased to HKD 407.3 million from HKD 478.1 million, while total liabilities significantly reduced to HKD 21.7 million from HKD 94.0 million [6]. - The company anticipates continued volatility in ICs and NAND flash wafer prices, impacting future revenue stability [8]. - Other losses included an additional provision of approximately HKD 60.4 million for loss contracts due to unexpected costs exceeding anticipated economic benefits [11]. - The company maintained a net asset value of HKD 385.6 million, slightly up from HKD 384.1 million in the previous year [6]. - The group anticipates growth opportunities in the electronic components industry driven by advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics [13]. Asset and Liability Management - As of December 31, 2024, the current ratio is approximately 18.1 times, significantly up from 4.8 times in 2023 [14]. - Total assets as of December 31, 2024, are approximately HKD 407.3 million, down from HKD 478.1 million in 2023 [14]. - The group’s capital debt ratio is approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023 [14]. - Inventory held as of December 31, 2024, is approximately HKD 188.8 million, a decrease from HKD 329.8 million in 2023 [15]. - Prepayments for inventory purchases amount to approximately HKD 70.6 million as of December 31, 2024, down from HKD 102.0 million in 2023 [16]. - Trade receivables as of December 31, 2024, are approximately HKD 98.7 million, with an expected credit loss provision of about HKD 0.3 million [18]. - Cash and cash equivalents are approximately HKD 23.3 million as of December 31, 2024, an increase from HKD 19.5 million in 2023 [19]. - The group has no borrowings as of December 31, 2024 [20]. Corporate Governance - The company has established a robust internal control system to ensure compliance and accountability, adhering to the corporate governance code as per the listing rules [40]. - The board consists of eight members, including three non-executive directors, two executive directors, and three independent non-executive directors, ensuring a balanced power structure [43]. - The company emphasizes a diverse board composition, considering various factors such as gender, age, ethnicity, and professional experience, to enhance governance effectiveness [48]. - The company has implemented an anti-corruption policy and reporting mechanism to promote ethical behavior and compliance among employees [41]. - The board has mechanisms in place to ensure independent viewpoints are considered, including encouraging active participation from independent non-executive directors [47]. - The company is currently seeking a suitable candidate for the CEO position, which has been vacant since July 18, 2019 [46]. - The company has adopted a code of conduct for securities trading by directors, ensuring compliance with the standards set forth in the listing rules [42]. - The board conducts annual reviews of its diversity policy and its effectiveness in achieving measurable goals [48]. Employee Relations and Compensation - The total salary and related costs for the 16 employees as of December 31, 2024, amount to approximately HKD 6.6 million [30]. - The company has established an annual review system to assess employee performance, which forms the basis for salary increases, bonuses, and promotions [30]. - The board believes in maintaining a good relationship with employees [30]. - The company has adopted a share option scheme to reward directors and eligible employees based on individual performance [30]. - The company has maintained a zero-tolerance policy towards any form of discrimination and has not reported any incidents of workplace discrimination or harassment this year [190]. - The company offers competitive and fair compensation and benefits to attract high-quality talent, with regular salary reviews to recognize employee contributions [190]. Risk Management - The company has established a risk management and internal control system to minimize procurement price risks and protect assets [80]. - The board believes the risk management and internal control systems are adequate and effective as of December 31, 2024 [82]. - The main risks faced by the company include credit risk, currency risk, and liquidity risk [160]. Environmental, Social, and Governance (ESG) Initiatives - The company is committed to environmental responsibility by managing its operational impact and improving resource efficiency [153]. - The company has established an Environmental, Social, and Governance (ESG) working group to assess and manage ESG-related risks [166]. - The ESG report emphasizes the importance of stakeholder engagement and has conducted a materiality assessment to identify key concerns [167][171]. - The company has implemented an environmental strategy focused on "saving, reusing, and recycling" to enhance energy efficiency and reduce carbon emissions [179]. - The company has established a collection area for recyclable materials, including paper, plastic, and metal, to support waste recycling efforts [175]. - The company is committed to complying with all relevant environmental laws and regulations applicable to its operations [172]. - The company has not recorded any significant non-compliance issues with applicable environmental protection laws and regulations as of December 31, 2024 [186]. Shareholder Relations - The board is committed to effective communication with shareholders to enhance investor relations and ensure timely disclosure of information [88]. - Shareholders holding at least 10% of the paid-up capital can request the board to convene a special general meeting [89]. - The company has updated its articles of association to comply with the latest regulatory requirements regarding paperless listing systems [93]. - The company reported total distributable reserves of approximately HKD 262,991,000 as of December 31, 2024, compared to HKD 233,372,000 in 2023, reflecting an increase of about 12.5% [107]. Compliance and Legal Matters - The company has adhered to relevant laws and regulations that significantly impact its business operations [151]. - The company has implemented appropriate internal controls and quality control measures to ensure compliance with the Sale of Goods Ordinance [156]. - The group complies with all applicable laws and regulations related to product responsibility, with no known violations during the year [199]. - The group has adopted high-standard security and confidentiality measures to protect stakeholders' personal data [200].

Financial Performance - For the fiscal year ending December 31, 2024, the company reported total revenue of HKD 519,699,000, a decrease of 46% compared to HKD 961,291,000 in the previous year[2] - The cost of sales for the same period was HKD 490,029,000, resulting in a gross profit of HKD 29,670,000, compared to a gross loss of HKD 35,603,000 in the previous year[2] - The net profit attributable to the company's owners for the year was HKD 1,311,000, a significant recovery from a net loss of HKD 52,705,000 in the previous year[2] - The basic and diluted earnings per share improved to HKD 0.77 from a loss of HKD 31.10 in the previous year[2] - The company reported other income of HKD 243,000 for the year ended December 31, 2024, compared to HKD 69,000 in 2023, indicating a significant increase[32] - The net other losses for the year ended December 31, 2024, amounted to HKD 12,828,000, compared to HKD 548,000 in 2023, reflecting a substantial increase in losses[33] - The financing costs for the year ended December 31, 2024, were HKD 23,000, down from HKD 43,000 in 2023, showing a decrease in financing expenses[34] - The company reported a profit attributable to owners of HKD 1,311,000 in 2024, a significant recovery from a loss of HKD 52,705,000 in 2023[39] - The gross profit for the year was approximately HKD 29.7 million, a turnaround from a gross loss of HKD 35.8 million in 2023, resulting in a gross margin of 5.7% compared to a gross loss margin of 3.7% in the previous year[54][56] Assets and Liabilities - The company's total assets decreased to HKD 407,309,000 from HKD 478,117,000, reflecting a decline of approximately 15%[5] - Current assets were reported at HKD 386,155,000, down from HKD 451,652,000, indicating a reduction of about 14%[5] - The company's total equity increased slightly to HKD 385,570,000 from HKD 384,114,000, showing a marginal growth of 0.4%[5] - Trade receivables, net of impairment, amounted to HKD 98,746,000 in 2024, compared to zero in 2023, indicating an increase in credit sales[44] - As of December 31, 2024, the current ratio was approximately 18.1 times, up from 4.8 times in 2023[59] - Total assets as of December 31, 2024, were approximately HKD 407.3 million, down from HKD 478.1 million in 2023[59] - The company's capital debt ratio was approximately 5.3% as of December 31, 2024, compared to 19.7% in 2023[59] - Inventory held as of December 31, 2024, was approximately HKD 188.7 million, down from HKD 329.8 million in 2023[62] - Trade receivables amounted to approximately HKD 98.7 million as of December 31, 2024, with an expected credit loss provision of approximately HKD 0.3 million[65] - Cash and cash equivalents were approximately HKD 23.3 million as of December 31, 2024, compared to HKD 19.5 million in 2023[66] - The company had no borrowings as of December 31, 2024[67] Business Operations - The company is primarily engaged in the sale of health products and electronic components, with a focus on expanding its market presence[9] - The company has focused solely on the electronic components business in 2024, with no sales from health products and food[52] - The company completed the sale of its entire interest in Hong Wang Holdings Limited on November 28, 2024[70] - The company has adopted a diversified strategy to optimize product structure and supply chain, aiming for stable business operations amid industry fluctuations[54] - The company is actively developing its healthcare business and exploring opportunities for collaboration with industry peers, focusing on various health products and foods[81] - The company aims to maintain a diversified product category and customer base strategy to uncover new business opportunities[81] - The company will monitor market changes and adjust strategies as needed to enhance profitability and resilience against risks, while striving to deliver substantial returns to investors[81] Future Outlook - The company has not yet applied any new accounting standards that are effective for the fiscal year starting January 1, 2024, which may impact future financial reporting[16] - The company is currently assessing the impact of the new Hong Kong Financial Reporting Standards on its consolidated financial statements, which may lead to significant changes in presentation and disclosure[20] - The company anticipates that the demand for ICs and NAND flash wafers will fluctuate in the second half of 2024, impacting overall pricing trends[53] - Strong demand in the smartphone and server markets is anticipated to significantly boost memory demand, with AI-enabled smart devices likely accelerating replacement cycles in the mid to long term[81] - The gradual development of advanced technologies such as third-generation semiconductor materials, 5G, AI, and automotive electronics is expected to create new growth opportunities in the electronic components industry[81] Dividends and Shareholder Returns - The company did not recommend any dividends for the years ended December 31, 2024, and 2023[43] - The board does not recommend the payment of a final dividend for the year[75] - The basic earnings per share for the year ended December 31, 2024, will be calculated based on the profit attributable to the owners of the company and the weighted average number of ordinary shares issued[38] - The company adopted a stock option plan effective from June 27, 2024, which is valid for ten years, but no stock options have been granted under this plan to date, resulting in a zero impact on the weighted average number of shares issued this year[77] Segment Reporting - The company has identified its reportable segments based on the internal reports reviewed by the executive directors, focusing on different product lines[22] - The company has no inter-segment sales for the years ended December 31, 2024, and 2023, indicating that all revenue is generated from external customers in Hong Kong[30] - The company has not presented segment assets and liabilities as these amounts are not regularly reviewed by the chief operating decision maker for resource allocation and performance assessment[29]

Financial Performance - The group reported total revenue of approximately HKD 307.0 million from its electronic components business, a decrease from HKD 339.9 million in the previous period, primarily due to a decline in sales volume [10]. - Gross profit for the period was approximately HKD 42.9 million, compared to a gross loss of HKD 6.4 million in the previous period, indicating a successful turnaround despite lower sales volume [10]. - The group achieved a profit attributable to owners of approximately HKD 15.5 million, a significant improvement from a loss of HKD 112.1 million in the previous period [12]. - Revenue for the six months ended June 30, 2024, was HKD 306,970, a decrease of 9.7% compared to HKD 339,899 for the same period in 2023 [39]. - Gross profit for the same period was HKD 42,896, compared to a gross loss of HKD 6,419 in 2023, indicating a significant recovery [39]. - The net profit attributable to the owners of the company for the six months ended June 30, 2024, was HKD 15,548, a turnaround from a net loss of HKD 112,118 in the previous year [39]. - The electronic components segment generated revenue of HKD 306,970,000, while the health products segment reported no revenue, leading to a total revenue of HKD 306,970,000 for the first half of 2024 [50]. - The cost of sales for the electronic components segment was HKD 264,074,000, resulting in a segment performance of HKD 42,896,000, compared to a loss of HKD 6,419,000 in the same period of 2023 [50]. Loss Provisions and Expenses - The group recognized an additional loss provision of HKD 19.9 million due to unavoidable costs exceeding expected economic benefits from certain procurement contracts [11]. - A loss provision of approximately HKD 112.1 million was recorded during the interim period due to delays in fulfilling procurement contracts [22]. - The company recorded a net loss of HKD 19,868,000 in other losses for the first half of 2024, a significant reduction from a loss of HKD 99,185,000 in the same period of 2023 [53]. - Administrative expenses rose to HKD 7,406,000 in the first half of 2024, compared to HKD 6,528,000 in the same period of 2023 [50]. - The financing costs decreased to HKD 8,000 from HKD 26,000 in the same period of 2023, indicating improved cost management [54]. Assets and Liabilities - Total assets increased to HKD 525,266 as of June 30, 2024, up from HKD 478,117 as of December 31, 2023, reflecting a growth of 9.8% [40]. - Current assets rose to HKD 500,009, compared to HKD 451,652 at the end of 2023, marking an increase of 10.7% [40]. - Current liabilities increased significantly to HKD 125,457 from HKD 94,003, an increase of 33.4% [41]. - The group held inventory of approximately HKD 375.3 million as of June 30, 2024, up from HKD 329.8 million on December 31, 2023 [16]. - Prepayments for inventory purchases amounted to approximately HKD 117.5 million as of June 30, 2024, compared to HKD 102.0 million on December 31, 2023 [17]. - Trade and other receivables rose to HKD 122,352, up from HKD 102,342, reflecting a growth of 19.6% [40]. Shareholder Information - As of June 30, 2024, the company had a total of 169,445,000 issued shares, with 89,248,577 shares held by controlled corporations [24]. - The major shareholder,拓陞, holds 89,248,577 shares, representing 52.67% of the total shares [28]. - The beneficial ownership of the major shareholders includes 黃志群 with 80% and 林捷 with 20% of拓陞's shares [26]. - The company has a consistent shareholder structure with significant control by a few entities, ensuring stability in governance [28]. - The company’s issued and fully paid ordinary shares as of June 30, 2024, were 169,445 thousand shares, reflecting adjustments due to a share consolidation [68]. Corporate Governance - The audit committee consists of three independent non-executive directors, ensuring effective risk management and internal control systems [37]. - The audit committee reviewed the financial performance for the six months ending June 30, 2024, and confirmed that the interim consolidated financial statements were prepared in accordance with applicable standards and regulations [38]. - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value and accountability [35]. - The company has adopted a code of conduct for securities trading by directors, ensuring compliance with the standards set out in the listing rules [36]. Future Outlook and Investments - Future growth opportunities are anticipated in the electronic components industry driven by advancements in third-generation semiconductor materials, 5G technology, AI, and automotive electronics [13]. - The group plans to invest in production facilities in China to provide additional value-added services, including technical support and product modifications [13]. - The group will pursue business expansion opportunities through investments or acquisitions of promising businesses or projects to maximize long-term shareholder value [14]. Stock Options and Dividends - The new stock option plan was adopted on June 27, 2024, for a duration of ten years, aimed at rewarding contributions to the group's growth and attracting talent [31]. - The stock option plan aims to align the interests of participants with those of shareholders to promote long-term financial performance [31]. - The total number of stock options available for grant under the new plan as of June 27, 2024, and June 30, 2024, is 16,944,500 shares, representing approximately 10% of the company's issued share capital as of the report date [33]. - The company did not recommend any interim dividend for the period [23]. - The company did not declare any dividends for the six months ended June 30, 2024, nor for the period following the report [59].

Financial Performance - For the six months ended June 30, 2024, the company reported revenue of HKD 306,970,000, a decrease of 9.7% compared to HKD 339,899,000 for the same period in 2023[1] - The gross profit for the same period was HKD 42,896,000, a significant improvement from a gross loss of HKD 6,419,000 in the previous year[1] - The operating profit before tax for the six months ended June 30, 2024, was HKD 15,548,000, compared to an operating loss of HKD 112,118,000 in the prior period[2] - The total comprehensive income for the period attributable to the company's owners was HKD 15,695,000, a turnaround from a loss of HKD 112,100,000 in the previous year[2] - The company reported a basic earnings per share of HKD 0.0918 for the current period, compared to a loss per share of HKD 0.662 in the previous year[2] - The group recorded total revenue of approximately HKD 307.0 million from the electronic components business, a decrease from HKD 339.9 million in the previous period, primarily due to a decline in sales volume[30] - The group reported a profit attributable to shareholders of approximately HKD 15.5 million for the interim period, a significant improvement from a loss of HKD 112.1 million in the previous period[32] Assets and Equity - The company's total assets increased to HKD 525,266,000 as of June 30, 2024, up from HKD 478,117,000 as of December 31, 2023[3] - Current assets rose to HKD 500,009,000, compared to HKD 451,652,000 at the end of 2023, indicating a growth of 10.7%[3] - The total equity attributable to the company's owners increased to HKD 399,809,000 from HKD 384,114,000, reflecting a growth of 4.1%[3] - The total assets included receivables of HKD 4,573,000 and prepayments for inventory purchases of HKD 117,513,000 as of June 30, 2024[24] - The group held inventory valued at approximately HKD 375.3 million as of June 30, 2024, an increase from HKD 329.8 million as of December 31, 2023[35] - The group’s prepayments for inventory purchases amounted to approximately HKD 117.5 million as of June 30, 2024, compared to HKD 102.0 million as of December 31, 2023[36] Operational Efficiency - The net other losses decreased significantly from HKD 99,185,000 in 2023 to HKD 19,868,000 in 2024, reflecting improved operational efficiency[14] - The segment performance for the same period in 2023 showed a loss of HKD 6,419,000, indicating a significant improvement year-over-year[12] - The group achieved a gross profit of approximately HKD 42.9 million, compared to a gross loss of HKD 6.4 million in the previous period, indicating a successful adjustment in operational strategy despite declining sales[30] Investments and Future Plans - The company is primarily engaged in the sale of electronic components and health products, indicating a focus on these sectors for future growth[5] - The group plans to invest in production facilities in China to provide additional value-added services, including technical support and product modification[33] - The group anticipates significant growth in the new energy sector, including electric vehicles and photovoltaic energy storage systems, which is expected to drive demand for related electronic products[33] Legal and Compliance - The company has undergone a share consolidation effective May 20, 2024, resulting in a legal capital of HKD 200 million divided into 500 million shares, of which 169,445,000 shares are issued and fully paid[40] - The audit committee, consisting of three independent non-executive directors, has reviewed the interim financial statements and confirmed they are prepared in accordance with applicable standards and regulations[48] - The company is currently seeking legal advice regarding ongoing litigation matters and will monitor their potential impact closely[41] Dividends and Shareholder Returns - The company did not declare any dividends for the six months ended June 30, 2024, nor for the period following the report[20] - The board of directors does not recommend the payment of any interim dividend for the period[45] Risks and Liabilities - The group has no significant contingent liabilities as of June 30, 2024[42] - The group has not encountered any significant foreign exchange risks due to its monetary assets and liabilities being primarily denominated in HKD and USD[39] - During the interim period, the group recorded a loss provision of approximately HKD 112.1 million due to delays in the performance of procurement contracts[41]

Qianhai Health Holdings Limited 前海健康控股有限 公 司 （於開曼群島註冊成立之有限公司） （股份代號: 911） 2023 年報 2023 ANNUAL REPORT (Stock Code: 911) 前海健康控股有限 公 司 (Incorporated in the Cayman Islands with limited liability) Qianhai Health Holdings Limited Qianhai Health Holdings Limited 前海健康控股有限 公 司 Annual Report 2023 目錄 | 公司資料 | 2 | | --- | --- | | 財務摘要 | 3 | | 管理層討論與分析 | 4 | | 董事及高級管理層之履歷詳情 | 9 | | 企業管治及其他資料 | 13 | | 董事會報告 | 25 | | 環境、社會及管治報告 | 39 | | 獨立核數師報告 | 50 | | 綜合損益表 | 56 | | 綜合全面收益表 | 57 | | 綜合財務狀況表 | 58 | | 綜合權益變動表 | 60 | | 綜合現 ...

Financial Performance - For the year ended December 31, 2023, the company reported total revenue of HKD 961,291,000, a decrease of 51.0% compared to HKD 1,961,704,000 in the previous year[2] - The cost of sales for the year was HKD 996,894,000, resulting in a gross loss of HKD 35,603,000, compared to a gross profit of HKD 76,482,000 in the previous year[2] - The net loss attributable to the owners of the company for the year was HKD 52,705,000, significantly improved from a loss of HKD 233,703,000 in the previous year, representing a reduction of 77.5%[2] - The basic and diluted loss per share for the year was HKD 3.11, compared to HKD 13.79 in the previous year[2] - The group reported a loss before tax of HKD 52.705 million for the year ended December 31, 2023, compared to a loss of HKD 233.703 million in 2022[24] - The group recognized other income of HKD 69, down from HKD 452 in 2022, indicating a decline of about 84.7%[29] - The group had a net loss from other (losses)/gains of HKD 548 in 2023, compared to a net loss of HKD 308.176 million in 2022, showing a significant improvement[30] - The company recorded a loss attributable to shareholders of approximately HKD 52.7 million for the year, compared to a loss of approximately HKD 233.7 million in the previous year[58] Assets and Equity - Total assets decreased to HKD 478,117,000 from HKD 534,434,000, a decline of 10.5% year-over-year[5] - Total equity attributable to the owners of the company decreased to HKD 384,114,000 from HKD 436,705,000, a decrease of 12.0%[5] - Non-current assets in Hong Kong decreased to HKD 26.465 million in 2023 from HKD 28.898 million in 2022, a decline of approximately 8.4%[27] - As of December 31, 2023, the company's total assets were approximately HKD 478.1 million, down from approximately HKD 534.4 million in 2022[62] Liquidity and Cash Flow - Cash and cash equivalents increased significantly to HKD 19,525,000 from HKD 1,642,000, indicating improved liquidity[5] - The current ratio as of December 31, 2023, was approximately 4.8 times, compared to 5.2 times in 2022[62] - The company’s cash and cash equivalents were approximately HKD 19.5 million as of December 31, 2023, compared to approximately HKD 1.6 million in 2022[68] - The company has no borrowings as of December 31, 2023[69] Revenue Breakdown - Revenue from health products was HKD 7.157 million, down from HKD 9.482 million in 2022, a decrease of about 24.5%[22] - Revenue from electronic components was HKD 954.134 million, down from HKD 1,952.222 million in 2022, a decrease of approximately 51.1%[22] - Health product sales generated only about HKD 7.2 million in revenue for the year, indicating a focus shift towards the electronic components business[55] - Revenue from the electronic components business decreased by approximately 51.1% to about HKD 954.1 million in 2023, down from HKD 1,952.2 million in the previous year[53] Inventory and Receivables - Inventory decreased to HKD 329,785,000 from HKD 380,461,000, a reduction of 13.3%[5] - Trade and other receivables totaled HKD 102.3 million in 2023, a decrease from HKD 123.4 million in 2022, reflecting a decline of about 17.1%[41] - The company’s trade receivables aged 91 to 180 days were zero in 2023, down from HKD 2.53 million in 2022[44] - The company has no trade receivables as of December 31, 2023, and wrote off bad debts of approximately HKD 2.5 million during the year[67] Corporate Governance and Future Plans - The company is committed to high standards of corporate governance to protect shareholder interests and enhance corporate value[80] - The company plans to invest in factories in China to provide additional value-added services, including support, modification, assembly, packaging, and testing services[60] - The company aims to expand its product portfolio and improve profitability by obtaining additional distribution rights from upstream manufacturers[60] Dividends and Shareholder Information - The company did not declare any dividends for the years ended December 31, 2023, and December 31, 2022[40] - The board of directors does not recommend a final dividend for the year, consistent with the previous year[77] - The annual general meeting is scheduled for June 20, 2024, with a suspension of share transfer registration from June 17 to June 20, 2024[85] - The annual performance announcement will be published on the stock exchange and the company's website, with a full annual report to be sent to shareholders[86] Legal and Compliance - The company is facing a legal claim from a supplier for approximately CAD 2.8 million (approximately HKD 16.8 million), but management believes the claim lacks evidence and does not expect a significant adverse impact on the overall financial position[72] - The audit committee, consisting of three independent non-executive directors, reviewed the financial statements and confirmed compliance with applicable accounting standards[82]

Financial Performance - The semiconductor business revenue decreased by approximately 71.9% to about HKD 337.2 million compared to the previous period's revenue of approximately HKD 1,201.3 million[8]. - Revenue for the six months ended June 30, 2023, was HKD 339,899,000, a decrease of 71.7% compared to HKD 1,201,279,000 for the same period in 2022[50]. - The company recorded a loss attributable to shareholders of approximately HKD 112.1 million for the interim period, compared to a profit of approximately HKD 19.6 million in the previous period[19]. - The company reported a pre-tax loss of HKD 112,118,000 for the six months ended June 30, 2023, compared to a profit of HKD 19,608,000 in the same period of 2022[82]. - The company recorded a total comprehensive loss of HKD 112,118,000 for the six months ended June 30, 2023, compared to a loss of HKD 19,608,000 in the same period of 2022[56]. - Basic loss per share for the period was HKD 0.0662, compared to earnings of HKD 0.0116 per share in the previous year[50]. - The company did not recommend the payment of an interim dividend for the interim period[27]. Assets and Liabilities - Total assets as of June 30, 2023, were approximately HKD 417.5 million, a decrease from approximately HKD 534.4 million as of December 31, 2022[20]. - Current assets decreased to HKD 389,791,000 from HKD 505,536,000, a decline of 23%[52]. - The total equity attributable to the owners of the company was HKD 324,605,000, down from HKD 436,705,000, reflecting a decrease of 25.7%[52]. - As of June 30, 2023, total liabilities decreased to HKD 92,868,000 from HKD 97,729,000, representing a reduction of approximately 5.4% year-over-year[54]. - The company has a low debt-to-asset ratio of approximately 4.5% as of June 30, 2023, compared to 5.5% as of December 31, 2022[20]. - The company recorded an expected credit loss provision of HKD (2,530,000) for the first half of 2023, with inventory provisions amounting to HKD (113,405,000)[70]. Inventory and Cash Flow - The group recorded an inventory provision of approximately HKD 113.4 million during the interim period, which was not present in the previous period[15]. - Inventory decreased by approximately 28.3% from about HKD 380.5 million (net of inventory provisions) as of December 31, 2022, to about HKD 272.6 million as of June 30, 2023[21]. - Cash and cash equivalents at the end of the period were HKD 9,165,000, down from HKD 163,428,000 at the end of June 2022, indicating a decrease of approximately 94.4%[58]. - The company reported a net cash inflow from operating activities of HKD 7,895,000 for the six months ended June 30, 2023, a significant decline from HKD 168,515,000 in the same period last year[58]. Business Strategy and Market Outlook - The group plans to invest in factories in China to provide additional value-added services, including support, modification, assembly, packaging, and testing services[12]. - The group is exploring potential investments in food processing and raw material extraction factories in Taiwan and China to expand its health business[12]. - The group aims to diversify its product range and customer base while monitoring market conditions to maintain a strong competitive advantage[13]. - The group anticipates that the semiconductor market will continue to expand in the coming years due to rising demand from renewable energy and electric vehicles[12]. - The health business is actively tracking market demand and supply trends to optimize its product portfolio and business strategy[9]. - Future outlook remains uncertain due to the significant losses and reduced cash flow, which may impact market expansion strategies[60]. Shareholder Information - As of June 30, 2023, the company has a total of 1,694,450,000 shares issued[40]. - Major shareholder 拓陞 holds 892,485,771 shares, representing 52.67% of the total shares[35]. - The company has a significant concentration of ownership, with major shareholders holding over 50% of the shares[35]. - The company has a stock option plan that allows for the issuance of options up to 30% of the total issued shares at any time[39]. - The stock option plan was adopted on June 9, 2014, and will expire on June 8, 2024[39]. - The company has no knowledge of any other individuals holding 5% or more of the shares as of June 30, 2023[38]. Operational Challenges - The semiconductor segment recorded a gross loss of approximately HKD 6.4 million, down from a gross profit of approximately HKD 28.2 million in the previous period[14]. - The health business generated only about HKD 2.7 million in revenue during the interim period due to the adverse effects of the COVID-19 pandemic[9]. - The company will continue to attract new customers to expand its customer base despite ongoing market challenges in the semiconductor industry[18]. - The company has not reported any new product launches or technological advancements during this period[60]. - The company continues to focus on its core business segments: electronic components and health products, with no mention of mergers or acquisitions in the current report[66].

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何 部分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前 海 健 康 控 股 有 限 公司 （於開曼群島註冊成立的有限公司） 911 （股份代號： ） 截至二零二三年六月三十日止六個月的 中期業績公告 前海健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（「本集團」）截至二零二三年六月三十日止六個月（「本中期期間」）的未經審 核簡明綜合中期業績，連同截至二零二二年六月三十日止同期（「上一期間」）的比較 數字如下： 簡明綜合損益及其他全面收益表 截至二零二三年六月三十日止六個月 截至六月三十日止六個月 二零二三年 二零二二年 附註 千港元 千港元 ...

Financial Performance - The company reported a revenue of HKD 1,961,704,000 for 2022, a significant increase of approximately 592.2% compared to HKD 283,398,000 in 2021[6] - Gross profit for the year was HKD 76,482,000, up from HKD 16,038,000 in the previous year[6] - The company experienced an operating loss of HKD 233,703,000, compared to a loss of HKD 888,000 in 2021[6] - The net asset value per share decreased to HKD 0.26 from HKD 0.40 in the previous year[6] - The company recorded a net loss attributable to shareholders of approximately HKD 233.7 million, compared to a loss of about HKD 0.9 million in the previous year[24] - The total reserves available for distribution to shareholders as of December 31, 2022, amounted to approximately HKD 356,564,000, down from HKD 546,407,000 in 2021[122] - The company did not recommend any dividend payment for the year, consistent with the previous year[119] Inventory and Supply Chain - The company holds inventory valued at approximately HKD 1,876,000,000, with over 98% consisting of semiconductor materials[10] - Inventory value as of December 31, 2022, was approximately HKD 380.5 million, a decrease of about 16.4% from approximately HKD 455.1 million a year earlier[26] - The company recorded an inventory provision of approximately HKD 238.0 million due to a decline in semiconductor market prices exceeding 30% in the last quarter of the year[21] - The semiconductor industry faced significant price declines in the second half of 2022, with prices dropping over 20% to 30% in the last quarter[10] - The company aims to optimize its product mix in response to weakening market demand[11] - The company has established a main purchase agreement with a major supplier in China to secure a stable supply of electronic components[9] Business Expansion and Strategy - The health business generated only HKD 9,500,000 in revenue, accounting for approximately 0.5% of total revenue[13] - The company is exploring potential collaborations with well-known online and offline retail platforms in Hong Kong and China to expand its health product offerings[14] - The company plans to establish subsidiaries in China and Taiwan to expand its business coverage and explore potential investments in food processing and raw material extraction factories[15] - The company aims to enhance its product portfolio by sourcing high-quality new products from manufacturers in China, Taiwan, and Thailand, and plans to invest in factories in China to provide additional value-added services[17] Corporate Governance - The company is committed to high standards of corporate governance, adhering to the principles of the Corporate Governance Code as per the listing rules[48] - The board consists of a total of eight directors, including four non-executive directors, one executive director, and three independent non-executive directors[51] - The company emphasizes the importance of a diverse board composition, considering factors such as gender, age, ethnicity, and professional experience in its diversity policy[56] - The company has established a mechanism to ensure independent viewpoints are obtained in board decisions, encouraging active participation from independent non-executive directors[55] - The company has implemented a robust internal control system to ensure effective monitoring and checks and balances[48] Risk Management - The group faces major risks including credit risk, currency risk, and liquidity risk as of December 31, 2022[176] - The board has established a robust risk management and internal control system to minimize procurement price risks and protect the group's assets[92] - The risk management and internal control measures are deemed effective in assessing and managing overall procurement price risks[92] - The audit committee reviews the effectiveness of the risk management and internal control systems annually, ensuring sufficient resources and staff qualifications in accounting and financial reporting[93] Employee and Stakeholder Engagement - The group provides various employee benefits, including mandatory provident fund, medical insurance, and performance-based discretionary bonuses[175] - The group recognizes the importance of stakeholder engagement for its success and has conducted a materiality assessment to understand key concerns[182] - The group has established effective internal control systems to enhance operational efficiency and deliver environmental and social benefits to stakeholders[186] Environmental Responsibility - The company is committed to sustainable development and has implemented waste recycling initiatives in its operations[170] - The company's direct carbon emissions for the year were 2.77 tons, a decrease of 79.5% from 13.49 tons in the previous year[189] - Indirect carbon emissions amounted to 22.29 tons, down 8.7% from 24.41 tons in the previous year[189] - Total energy consumption was 34,203 kWh, a reduction of 7.1% from 36,808 kWh in the previous year[194] - The company is committed to implementing energy-saving strategies and educating employees on environmental awareness[193] Shareholder Information - The issued share capital of the company remained unchanged during the year[120] - As of December 31, 2022, the directors and the CEO held a total of 892,485,771 shares, representing 52.67% of the company's equity[142] - The company has a share option plan approved by shareholders on June 9, 2014, aimed at rewarding selected participants for their contributions[152] - The maximum number of shares available for issuance under the plan is 170,040,500 shares, representing 10% of the issued ordinary share capital as of June 13, 2017[155]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不對因本公告全部或任何部 分內容而產生或因依賴該等內容而引致的任何損失承擔任何責任。 Qianhai Health Holdings Limited 前 海 健 康 控 股 有 限 公司 （於開曼群島註冊成立的有限公司） 911 （股份代號： ） 截至二零二二年十二月三十一日止年度的 年度業績公告 前海健康控股有限公司（「本公司」）董事（「董事」）會（「董事會」）欣然宣佈本公司及其 附屬公司（「本集團」）截至二零二二年十二月三十一日止年度（「本年度」）的經審核綜 合業績，連同截至二零二一年十二月三十一日止年度同期（「上一年度」）的比較數字 如下： 綜合損益表 截至二零二二年十二月三十一日止年度 二零二二年 二零二一年 附註 千港元 千港元 3 1,961,704 283,398 收益 4 (1,885,222) (267,360) 銷售成本 76,482 16,038 毛利 ...